| Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated HIV-1 Infected Controllers | HIV-1 Infection |
Drug: Vesatolimod; Drug: Vesatolimod Placebo; Drug: ART |
| A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects | HIV |
Drug: PRO 140; Drug: Placebo; Drug: Optimized Background Regimen |
| HSV Herpes |
Drug: Pritelivir Drug: Foscarnet |
|
| Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection | HIV | Drug: PRO 140 |
| A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care | HIV-1 | Drug: DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC |
Currently Enrolling Studies
jsukhram
2018-05-25T19:02:43+00:00